Côd QR

Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

Background: Up to 60% of metastatic breast cancer (mBC) cases historically classified as human epidermal growth factor receptor 2 (HER2)-negative may be HER2-low, expanding options towards new HER2 targeted treatments. Greater understanding of the current therapeutic journey of this population can h...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Shanu Modi, Danalyn Byng, Suyuan Zhang, Yan Xiong, Shannon Hunter, Kyle Dunton, Tara Harding, William Jacot
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Elsevier 2026-04-01
Cyfres:Breast
Pynciau:
Metastatic breast cancer
Real-world evidence
HER2-Low
HR+
Trastuzumab deruxtecan
Mynediad Ar-lein:http://www.sciencedirect.com/science/article/pii/S0960977626000317
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg